These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 22833690)
1. Synthesis and characterization of acetalated dextran polymer and microparticles with ethanol as a degradation product. Kauffman KJ; Do C; Sharma S; Gallovic MD; Bachelder EM; Ainslie KM ACS Appl Mater Interfaces; 2012 Aug; 4(8):4149-55. PubMed ID: 22833690 [TBL] [Abstract][Full Text] [Related]
2. Synthesis, optimization, and characterization of camptothecin-loaded acetalated dextran porous microparticles for pulmonary delivery. Meenach SA; Kim YJ; Kauffman KJ; Kanthamneni N; Bachelder EM; Ainslie KM Mol Pharm; 2012 Feb; 9(2):290-8. PubMed ID: 22149217 [TBL] [Abstract][Full Text] [Related]
3. Degradation of acetalated dextran can be broadly tuned based on cyclic acetal coverage and molecular weight. Chen N; Collier MA; Gallovic MD; Collins GC; Sanchez CC; Fernandes EQ; Bachelder EM; Ainslie KM Int J Pharm; 2016 Oct; 512(1):147-157. PubMed ID: 27543351 [TBL] [Abstract][Full Text] [Related]
4. Efficient delivery of the toll-like receptor agonists polyinosinic:polycytidylic acid and CpG to macrophages by acetalated dextran microparticles. Peine KJ; Bachelder EM; Vangundy Z; Papenfuss T; Brackman DJ; Gallovic MD; Schully K; Pesce J; Keane-Myers A; Ainslie KM Mol Pharm; 2013 Aug; 10(8):2849-57. PubMed ID: 23768126 [TBL] [Abstract][Full Text] [Related]
5. Optimization of rapamycin-loaded acetalated dextran microparticles for immunosuppression. Kauffman KJ; Kanthamneni N; Meenach SA; Pierson BC; Bachelder EM; Ainslie KM Int J Pharm; 2012 Jan; 422(1-2):356-63. PubMed ID: 22037446 [TBL] [Abstract][Full Text] [Related]
8. Development and physicochemical characterization of acetalated dextran aerosol particle systems for deep lung delivery. Wang Z; Gupta SK; Meenach SA Int J Pharm; 2017 Jun; 525(1):264-274. PubMed ID: 28450166 [TBL] [Abstract][Full Text] [Related]
9. Acetalated Dextran: A Tunable and Acid-Labile Biopolymer with Facile Synthesis and a Range of Applications. Bachelder EM; Pino EN; Ainslie KM Chem Rev; 2017 Feb; 117(3):1915-1926. PubMed ID: 28032507 [TBL] [Abstract][Full Text] [Related]
10. Acetalated dextran based nano- and microparticles: synthesis, fabrication, and therapeutic applications. Wang S; Fontana F; Shahbazi MA; Santos HA Chem Commun (Camb); 2021 Apr; 57(35):4212-4229. PubMed ID: 33913978 [TBL] [Abstract][Full Text] [Related]
11. Biodegradable and pH-Responsive Acetalated Dextran (Ac-Dex) Nanoparticles for NIR Imaging and Controlled Delivery of a Platinum-Based Prodrug into Cancer Cells. Braga CB; Perli G; Becher TB; Ornelas C Mol Pharm; 2019 May; 16(5):2083-2094. PubMed ID: 30901218 [TBL] [Abstract][Full Text] [Related]
12. Tunable degradation of acetalated dextran microparticles enables controlled vaccine adjuvant and antigen delivery to modulate adaptive immune responses. Chen N; Johnson MM; Collier MA; Gallovic MD; Bachelder EM; Ainslie KM J Control Release; 2018 Mar; 273():147-159. PubMed ID: 29407676 [TBL] [Abstract][Full Text] [Related]
14. In Vivo and Cellular Trafficking of Acetalated Dextran Microparticles for Delivery of a Host-Directed Therapy for Salmonella enterica Serovar Typhi Infection. Johnson MM; Collier MA; Hoang KV; Pino EN; Graham-Gurysh EG; Gallovic MD; Zahid MSH; Chen N; Schlesinger L; Gunn JS; Bachelder EM; Ainslie KM Mol Pharm; 2018 Nov; 15(11):5336-5348. PubMed ID: 30296381 [TBL] [Abstract][Full Text] [Related]
15. Tumor Responsive and Tunable Polymeric Platform for Optimized Delivery of Paclitaxel to Treat Glioblastoma. Graham-Gurysh EG; Moore KM; Schorzman AN; Lee T; Zamboni WC; Hingtgen SD; Bachelder EM; Ainslie KM ACS Appl Mater Interfaces; 2020 Apr; 12(17):19345-19356. PubMed ID: 32252517 [TBL] [Abstract][Full Text] [Related]
16. Sustained Delivery of Doxorubicin via Acetalated Dextran Scaffold Prevents Glioblastoma Recurrence after Surgical Resection. Graham-Gurysh E; Moore KM; Satterlee AB; Sheets KT; Lin FC; Bachelder EM; Miller CR; Hingtgen SD; Ainslie KM Mol Pharm; 2018 Mar; 15(3):1309-1318. PubMed ID: 29342360 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of a biodegradable microparticulate polymer as a carrier for Burkholderia pseudomallei subunit vaccines in a mouse model of melioidosis. Schully KL; Bell MG; Prouty AM; Gallovic MD; Gautam S; Peine KJ; Sharma S; Bachelder EM; Pesce JT; Elberson MA; Ainslie KM; Keane-Myers A Int J Pharm; 2015 Nov; 495(2):849-61. PubMed ID: 26428631 [TBL] [Abstract][Full Text] [Related]
18. Intracellular pH-sensitive PEG-block-acetalated-dextrans as efficient drug delivery platforms. Zhang Z; Chen X; Chen L; Yu S; Cao Y; He C; Chen X ACS Appl Mater Interfaces; 2013 Nov; 5(21):10760-6. PubMed ID: 24090231 [TBL] [Abstract][Full Text] [Related]
19. Electrospray encapsulation of toll-like receptor agonist resiquimod in polymer microparticles for the treatment of visceral leishmaniasis. Duong AD; Sharma S; Peine KJ; Gupta G; Satoskar AR; Bachelder EM; Wyslouzil BE; Ainslie KM Mol Pharm; 2013 Mar; 10(3):1045-55. PubMed ID: 23320733 [TBL] [Abstract][Full Text] [Related]
20. A novel enzymatically-mediated drug delivery carrier for bone tissue engineering applications: combining biodegradable starch-based microparticles and differentiation agents. Balmayor ER; Tuzlakoglu K; Marques AP; Azevedo HS; Reis RL J Mater Sci Mater Med; 2008 Apr; 19(4):1617-23. PubMed ID: 18214645 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]